Resveratrol attenuates high glucose-induced oxidative stress and cardiomyocyte apoptosis through AMPK

Molecular and Cellular Endocrinology

Volumn 412, Issue , 2015, Pages 85-94

  Guo, Shuang ^a   Yao, Qing ^a   Ke, Zhiqiang ^a   Chen, Hongguang ^a   Wu, Jiliang ^a   Liu, Chao ^a  

^a HUBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

AMPK; Apoptosis; Cardiomyocytes; NADPH; Resveratrol; ROS

Indexed keywords

CATALASE; GLUCOSE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOPROTEIN GP 91; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P47; PROTEIN P67; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RESVERATROL; SUPEROXIDE DISMUTASE; ADENYLATE KINASE; BAX PROTEIN, RAT; CARDIOTONIC AGENT; STILBENE DERIVATIVE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HEART MUSCLE CELL; LIPID PEROXIDATION; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; ANIMAL; CARDIAC MUSCLE CELL; CELL CULTURE; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; PHYSIOLOGY; PRECLINICAL STUDY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ADENYLATE KINASE; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARDIOTONIC AGENTS; CELL SURVIVAL; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION; GLUCOSE; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-BCL-2; RAC1 GTP-BINDING PROTEIN; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; STILBENES;

EID: 84931263991     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.05.034     Document Type: Article

References (42)

1. Ansley D.M., Wang B. Oxidative stress and myocardial injury in the diabetic heart. J. Pathol 2013, 229(2):232-241.
2. Balteau M., Tajeddine N., de Meester C., Ginion A., Des Rosiers C., Brady N.R., et al. NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1. Cardiovasc. Res 2011, 92(2):237-246.
3. Bernecker O.Y., Huq F., Heist E.K., Podesser B.K., Hajjar R.J. Apoptosis in heart failure and the senescent heart. Cardiovasc. Toxicol 2003, 3(3):183-190.
4. Bonnefont-Rousselot D., Bastard J.P., Jaudon M.C., Delattre J. Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab 2000, 26(3):163-176.
5. Cai L., Li W., Wang G., Guo L., Jiang Y., Kang Y.J. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 2002, 51(6):1938-1948.
6. Cave A.C., Brewer A.C., Narayanapanicker A., Ray R., Grieve D.J., Walker S., et al. NADPH oxidases in cardiovascular health and disease. Antioxid. Redox Signal 2006, 8(5-6):691-728.
7. Chaanine A.H., Hajjar R.J. AKT signalling in the failing heart. Eur. J. Heart Fail 2011, 13(8):825-829.
8. Chen K., Li G., Geng F., Zhang Z., Li J., Yang M., et al. Berberine reduces ischemia/reperfusion-induced myocardial apoptosis via activating AMPK and PI3K-Akt signaling in diabetic rats. Apoptosis 2014, 19(6):946-957.
9. Cheng P.W., Ho W.Y., Su Y.T., Lu P.J., Chen B.Z., Cheng W.H., et al. Resveratrol decreases fructose-induced oxidative stress, mediated by NADPH oxidase via an AMPK-dependent mechanism. Br. J. Pharmacol 2014, 171(11):2739-2750.
10. Dhalla N.S., Takeda N., Rodriguez-Leyva D., Elimban V. Mechanisms of subcellular remodeling in heart failure due to diabetes. Heart Fail. Rev 2014, 19(1):87-99.
11. Dolinsky V.W., Dyck J.R. Calorie restriction and resveratrol in cardiovascular health and disease. Biochim. Biophys. Acta 2011, 1812(11):1477-1489.
12. Drummond G.R., Selemidis S., Griendling K.K., Sobey C.G. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat. Rev. Drug Discov 2011, 10(6):453-471.
13. Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction?. Diabetes 2003, 52(1):1-8.
14. Fang Z.Y., Prins J.B., Marwick T.H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev 2004, 25(4):543-567.
15. Fiordaliso F., Li B., Latini R., Sonnenblick E.H., Anversa P., Leri A., et al. Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II- dependent. Lab. Invest 2000, 80(4):513-527.
16. Foo R.S., Mani K., Kitsis R.N. Death begets failure in the heart. J. Clin. Invest 2005, 115(3):565-571.
17. Forbes J.M., Cooper M.E. Mechanisms of diabetic complications. Physiol. Rev 2013, 93(1):137-188.
18. Gao L., Mann G.E. Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc. Res 2009, 82(1):9-20.
19. Gao R.Y., Mukhopadhyay P., Mohanraj R., Wang H., Horvath B., Yin S., et al. Resveratrol attenuates azidothymidine-induced cardiotoxicity by decreasing mitochondrial reactive oxygen species generation in human cardiomyocytes. Mol. Med. Rep 2011, 4(1):151-155.
20. Guo R., Li W., Liu B., Li S., Zhang B., Xu Y. Resveratrol protects vascular smooth muscle cells against high glucose-induced oxidative stress and cell proliferation in vitro. Med. Sci. Monit. Basic Res 2014, 20:82-92.
21. He T., Guan X., Wang S., Xiao T., Yang K., Xu X., et al. Resveratrol prevents high glucose-induced epithelial-mesenchymal transition in renal tubular epithelial cells by inhibiting NADPH oxidase/ROS/ERK pathway. Mol. Cell. Endocrinol 2015, 402:13-20.
22. Holthoff J.H., Woodling K.A., Doerge D.R., Burns S.T., Hinson J.A., Mayeux P.R. Resveratrol, a dietary polyphenolic phytoalexin, is a functional scavenger of peroxynitrite. Biochem. Pharmacol 2010, 80(8):1260-1265.
23. Huang J.P., Huang S.S., Deng J.Y., Chang C.C., Day Y.J., Hung L.M. Insulin and resveratrol act synergistically, preventing cardiac dysfunction in diabetes, but the advantage of resveratrol in diabetics with acute heart attack is antagonized by insulin. Free Radic. Biol. Med 2010, 49(11):1710-1721.
24. Kovacic P., Somanathan R. Multifaceted approach to resveratrol bioactivity: focus on antioxidant action, cell signaling and safety. Oxid. Med. Cell Longev 2010, 3(2):86-100.
25. Kovacic S., Soltys C.L., Barr A.J., Shiojima I., Walsh K., Dyck J.R. Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J. Biol. Chem 2003, 278(41):39422-39427.
26. Kuethe F., Sigusch H.H., Bornstein S.R., Hilbig K., Kamvissi V., Figulla H.R. Apoptosis in patients with dilated cardiomyopathy and diabetes: a feature of diabetic cardiomyopathy?. Horm. Metab. Res 2007, 39(9):672-676.
27. Kuroda J., Sadoshima J. NADPH oxidase and cardiac failure. J. Cardiovasc. Transl. Res 2010, 3(4):314-320.
28. Li H., Xia N., Forstermann U. Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide 2012, 26(2):102-110.
29. Li Y., Cao Z., Zhu H. Upregulation of endogenous antioxidants and phase 2 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle cells leads to cytoprotection against oxidative and electrophilic stress. Pharmacol. Res 2006, 53(1):6-15.
30. Lorenz P., Roychowdhury S., Engelmann M., Wolf G., Horn T.F. Oxyresveratrol and resveratrol are potent antioxidants and free radical scavengers: effect on nitrosative and oxidative stress derived from microglial cells. Nitric Oxide 2003, 9(2):64-76.
31. Ritchie R.H., Quinn J.M., Cao A.H., Drummond G.R., Kaye D.M., Favaloro J.M., et al. The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo. J. Mol. Cell. Cardiol 2007, 42(6):1119-1128.
32. Robertson R.P., Harmon J., Tran P.O., Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004, 53(Suppl. 1):S119-S124.
33. Rubler S., Dlugash J., Yuceoglu Y.Z., Kumral T., Branwood A.W., Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol 1972, 30(6):595-602.
34. Sasaki H., Asanuma H., Fujita M., Takahama H., Wakeno M., Ito S., et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009, 119(19):2568-2577.
35. Schilling J.D., Mann D.L. Diabetic cardiomyopathy: bench to bedside. Heart Fail. Clin 2012, 8(4):619-631.
36. Sugamura K., Keaney J.F. Reactive oxygen species in cardiovascular disease. Free Radic. Biol. Med 2011, 51(5):978-992.
37. Toth P., Tarantini S., Tucsek Z., Ashpole N.M., Sosnowska D., Gautam T., et al. Resveratrol treatment rescues neurovascular coupling in aged mice: role of improved cerebromicrovascular endothelial function and downregulation of NADPH oxidase. Am. J. Physiol. Heart Circ. Physiol 2014, 306(3):H299-H308.
38. Turan B., Tuncay E., Vassort G. Resveratrol and diabetic cardiac function: focus on recent in vitro and in vivo studies. J. Bioenerg. Biomembr 2012, 44(2):281-296.
39. Wold L.E., Ceylan-Isik A.F., Ren J. Oxidative stress and stress signaling: menace of diabetic cardiomyopathy. Acta Pharmacol. Sin 2005, 26(8):908-917.
40. Yao D., Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010, 59(1):249-255.
41. Zhang L., Pang S., Deng B., Qian L., Chen J., Zou J., et al. High glucose induces renal mesangial cell proliferation and fibronectin expression through JNK/NF-kappaB/NADPH oxidase/ROS pathway, which is inhibited by resveratrol. Int. J. Biochem. Cell Biol 2012, 44(4):629-638.
42. Zielonka J., Hardy M., Kalyanaraman B. HPLC study of oxidation products of hydroethidine in chemical and biological systems: ramifications in superoxide measurements. Free Radic. Biol. Med 2009, 46(3):329-338.